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Abstract
Gestational malaria is a multi-factorial syndrome leading to poor outcomes for both the mother and foetus.
Although an unusual increasing in the number of hospitalizations caused by Plasmodium vivax has been reported
in Brazil, mortality is rarely observed. This is a report of a gestational malaria case that occurred in the city of
Manaus (Amazonas State, Brazil) and resulted in foetal loss. The patient presented placental mixed-infection by
Plasmodium vivax and Plasmodium falciparum after diagnosis by nested-PCR, however microscopic analysis failed to
detect P. falciparum in the peripheral blood. Furthermore, as the patient did not receive proper treatment for P.
falciparum and hospitalization occurred soon after drug treatment, it seems that P. falciparum pathology was
modulated by the concurrent presence of P. vivax. Collectively, this case confirms the tropism towards the placenta
by both of these species of parasites, reinforces the notion that co-existence of distinct malaria parasites interferes
on diseases’ outcomes, and opens discussions regarding diagnostic methods, malaria treatment during pregnancy
and prenatal care for women living in unstable transmission areas of malaria, such as the Brazilian Amazon.
Background
In severe cases of Plasmodium falciparum infection,
clinical complications are associated with the sequestra-
tion of P. falciparum-infected erythrocytes (Pf-iE) within
microvasculature and placental syncytiotrophoblasts
[1-5]. Vivax malaria has long been considered a benign
infection; however, the malaria pigment of this species
has been detected in the placenta of Plasmodium vivax-
infected women [6]. Further, pregnant women infected
with P. vivax experience maternal anaemia, and some of
their babies present a low birth weight [6,7], which are
clinical features frequently associated with Pf-iE placen-
tal adhesion [1,2]. Despite the adverse pregnancy
outcomes associated with P. vivax infection [6], informa-
tion concerning epidemiology and clinical consequences
of vivax malaria during pregnancy is lacking.
In Brazil, where malaria incidence is almost exclusively
restricted to the Amazon (99.8% of the cases), P. vivax
was responsible for the majority (83.7%) of registered
cases in 2008. Plasmodium falciparum infections
accounted for 16.3% of cases, and Plasmodium malariae
infection was rarely observed [8]. Additionally, chloro-
quine-resistant strains of P. vivax have emerged in the
Brazilian Amazon [9].
Case presentation
A 19-year-old pregnant woman, estimated to be 35
weeks of gestation (WG), living on the boundary of the
city of Manaus - Amazon State (3.09S, 59.58W), sur-
rounded by the Amazon rainforest, was diagnosed for
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showed approximately 90,000 parasites/mm
3.I nB r a z i l ,
the microscopic examination of Giemsa-stained thick
blood smear is the official method for malaria diagnosis.
This was her fourth pregnancy, and she had no medical
history of previous abortion, stillbirth or pre-term deliv-
ery. The patient had three previous malaria episodes,
the last occurring two years ago. Additionally, she
reported a plasmodial infection during her third preg-
nancy. At the time, the patient was treated and no
further complications were observed.
She was given a three-day regimen (25 mg/kg) of oral
chloroquine, with four pills (150 mg each) administered
in the first day, followed by three pills on the two subse-
quent days. However, after the second dose, the patient
presented with vomiting, which led to cessation of the
drug treatment. The patient was subsequently trans-
ferred to a tertiary-care maternity hospital in Manaus,
where she was hospitalized until delivery. At the mater-
nity hospital, the patient presented symptoms of fever,
headache, jaundice, anorexia, chills and hypertension.
Urine sediment analysis revealed that bilirubin and bili-
ary pigments were three-fold above the standard levels.
Furthermore, blood analysis revealed slight anaemia (Ht
29.3%, Hb 10.1 g/dL) and leukocyte count were normal
(4,200 cells/mm
3), with 67% lymphocytes. Serological
tests for syphilis, toxoplasmosis, measles and HIV were
negative.
Two days after patient admission, another thick blood
smear was performed and no patent parasitaemia was
observed. Ultrasound analysis showed that foetal heart
rate tracings were stable and normal. While foetal cen-
tralization was not observed, the ultrasound did reveal
oligohydramnios (amniotic fluid index < 5.0 cm), abnor-
mal foetal symmetry and abnormal placental texture.
Although pregnancy was estimated to be 35 WG, with a
foetal weight of 2,500 g, according to the patient’sl a s t
menstruation date, foetal growth was approximately 38-
39 WG. Thus, the estimate of 35 WG after ultrasound
analysis might represent impairment of intra-uterine
growth. Two days later in a routine follow-up, an abnor-
mal foetal heart rate was observed. Another ultrasound
analysis was performed, and no foetal heartbeat was
detected, and oligohydramnios was observed. Next,
labour was induced by administration of oxytocin, and
foetal loss of a male weighing 2,670 g was confirmed.
No foetal autopsy was performed due to the lack of
authorization by relatives. Macroscopic examination of
the placenta revealed an abnormal dark colour; follow-
ing patient consent, a sample of the placental tissue was
collected for further microscopic and molecular analysis.
Molecular analysis of the placenta revealed a mixed
infection with P. falciparum and P. vivax.T a k e n
together, these findings suggest placental dysfunction
most likely associated with plasmodial infection, as
other common infectious diseases that cause the same
phenomenon were ruled out.
Because of the absence of parasite forms in the thick
blood smear performed at the maternity, the patient did
not receive any anti-malarial treatment during her stay
and immediately after being released from the hospital.
In the second month after foetus loss, nested-PCR ana-
lysis was conducted on the asymptomatic mother’sp e r -
ipheral blood and a P. falciparum-specific PCR product
was detected, despite the maintenance of negative thick
blood smears. At the time, the patient was treated with
artemether/lumefantrine for three days. Figure 1 sum-
marizes, in a chronological manner, the major events
reported in this case.
Methods
Molecular analysis
A small fraction (1 × 1 × 1 cm) of maternal placenta
was collected, frozen in liquid nitrogen and crushed in 2
mL of digestion buffer (100 mM NaCl, 10 mM Tris-
HCl, 25 mM EDTA and 0.5% SDS) before incubation
overnight at 37°C in the presence of proteinase K (0.1
mg/mL, Sigma). The DNA used for PCR amplification
was purified by two phenol/chloroform extractions, fol-
lowed by ethanol precipitation; DNA samples were
resuspended in water. Two samples of the patient’s per-
ipheral blood were collected, the first one at few hours
after the foetus loss and other approximated two
months later. Genomic DNA (gDNA) was purified using
the Charge Switch gDNA Blood Kit (Invitrogen) accord-
ing to the manufacturer’s protocol. To determine and
discriminate the presence of Plasmodium spp. gDNA in
the blood sample, sensitive nested-PCR was performed
using species-specific oligonucleotides based on human
malaria parasite genes for the 18S small subunit riboso-
mal RNA (ssrRNA) as described previously [10]. Impor-
tant, this set of oligonucleotides amplifies small amounts
of genetic material only from viable parasites [10]. As a
negative control, gDNA purified from a healthy placenta
or from the peripheral blood of a non-infected indivi-
dual was used. The products of these reactions were
analyzed on a 2% agarose gel stained with ethidium bro-
m i d e .T oe n s u r en e s t e d - P C Rs pecificity, amplification
products were directly cloned into the pGEM-T cloning
vector kit (Promega) and then analysed with the aid of
the MegaBace 500 automatic sequencer (GE - Health
care).
Nested-PCR results conducted with patient’sp l a c e n t a l
t i s s u ew e r ea l s oc o n f i r m e dby semi-nested multiplex
malaria PCR (SnM-PCR) (Additional file 1) assays as
described [11]. Because of the poor conditions of the
placental tissue collected histological analyses were not
conducted.
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Written and informed consent was sought and granted
from the patient who attended the tertiary-care mater-
nity hospital.
Results
The patient was diagnosed for P. vivax infection by thick
blood smear performed in a Health Center during her
pregnancy. To confirm this diagnosis and to investigate
placental vivax infection, we conducted nested-PCR analy-
sis of the placental tissue using species-specific oligonu-
cleotides. As expected, specific amplification of P. vivax
18S ssrRNA gene was detected (Figure 2). However, a
positive reaction was also observed after incubation with
P. falciparum-specific oligonucleotides (Figure 2); thus
revealing a mixed-species placental infection. Despite the
positive nested-PCR result, P. falciparum-infected erythro-
cytes were not detected in peripheral blood by the thick
blood smear before delivery. Nested-PCR analysis of
peripheral blood was also performed immediately after
foetal loss, and neither P. vivax- nor P. falciparum-specific
fragments were observed (Figure 2).
Discussion
Recent efforts by Brazilian authorities have led to a sig-
nificant reduction in malaria cases (456,000 in 2007 to
314,000 in 2009) and in the Amazonian Annual Parasi-
tological Index (API; 31.9 in 1999 to 12.8 in 2008) over
the last few years [8]. Nevertheless, disease incidence in
women and children less than 10 years of age increased
from 2003 to 2008; disease in women increased from
34.9 to 38.6%, while the incidence in children under 10
increased from 22 to 25.2% [8]. Indeed, in Manaus, an
unusual augmentation in the number of hospitalizations
of P. vivax-infected individuals has been reported over
the past years [12]. Brazilian malaria treatment policy
Figure 1 Schematic representation of the major events reported in this case. Diagnosis, treatment and symptoms are reported as they
occurred in a chronological manner. Following the P. vivax positive blood smear diagnosis, the patient remained hospitalized until delivery,
when placental tissue and mother’s peripheral blood samples were collected and molecular analyses were performed. Two months after foetal
loss, a new blood sample was collected, allowing P. falciparum molecular diagnosis by nested-PCR.
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gical cases. A combination of chloroquine and prima-
quine is used in uncomplicated P. vivax infections, while
artemether-lumefantrine is the choice to treat uncompli-
cated P. falciparum infections. In severe falciparum
malaria, intravenous administration of artemisinin deri-
vatives is recommended [13].
The relationship between P. vivax infection and preg-
nancy outcomes such as stillbirth and miscarriage
remains unclear in the literature. However, studies con-
ducted in Southeastern Asia indicate a correlation
between P. vivax infection and adverse pregnancy out-
comes, eventually leading to maternal anemia and low
birth weight, and with the presence of malaria pigment
in the placenta [6,7]. Furthermore, it has been shown an
increase in the frequency of P. falciparum infections in
pregnant women in a cohort of 1,699 childbearing
women in the Brazilian Amazon [14].
This is a case report of gestational malaria with foetal
loss, in which DNA of both P. vivax and P. falciparum
were amplified from infected placental tissue. In con-
trast, only P. vivax-infected erythrocytes (Pv-iE) were
found in patient peripheral blood following diagnosis by
Giemsa-stained thick blood smear. Although the
patient’s chloroquine treatment was incomplete, the uti-
lized diagnostic method failed to detect P. vivax in the
peripheral blood after treatment; thus showing some
efficacy of the drug treatment against this species of
parasite. Moreover, as the nested-PCR analysis con-
ducted by us detects only viable parasites, we assume
that both of these species of parasites were accumulated
or sequestered in the placenta and played a role in
pathology.
During the months that followed foetus loss, even
without a clear symptom, the patient was further tested
for malaria infection by thick blood smear in the health
center, and parasites were not detected in the peripheral
blood. However, a molecular diagnosis by nested-PCR
performed in the patient’s peripheral blood collected
two months after delivery detected only P. falciparum
(Additional file 2). Although immunological analyses
were not carried out, microscopically undetectable levels
of peripheral parasitaemia might suggest that this
woman presents an important acquired immunity
against P. falciparum.
It is not known by which means P. vivax can lead to
severe complications in pregnancy; even though a recent
report has shown the ability of Pv-iE to cytoadhere to
placental cryosections [15]. However, several reports
have shown that mixed-malaria species infection attenu-
ates the severity of P. falciparum p a t h o l o g yi nA s i aa n d
in Brazil [16-18]. Moreover, it has been recently shown
that in malaria mixed-species infections patients develop
higher levels of fever and antisera against P. vivax and
P. falciparum in comparison to patients with a single
infection [19], and competition between co-infecting
parasites for limited resources within a host consists in
a form of selective pressure directed from one species to
another [20]. Given that the patient was hospitalized
soon after chloroquine administration, it is most likely
that by disrupting the equilibrium between these two
parasites an exacerbation of the clinical signs by the
most virulent species contributed to foetal death. None-
t h e l e s s ,t h ep o s s i b i l i t yt h a tP. falciparum erythrocytic
infection has occurred in the period between chloro-
quine treatment and delivery cannot be ruled out.
Conclusions
Collectively, this case reinforces the notion that by inter-
fering in the homeostasis of two distinct species of Plas-
modium parasites in mixed-infections symptoms
provoked by the more virulent species can exacerbate.
Figure 2 T h ep r e s e n c eo fP. falciparum- and P. vivax-infected erythrocytes in the placenta collected after foetal loss. Agarose gel
electrophoresis of nested-PCR amplified products in the presence of species-specific human malaria parasite oligonucleotides (VIV or FAL,
specific for P. vivax or P. falciparum, respectively) based on the parasite small subunit ribosomal RNA (ssrRNA) gene. Both P. vivax and P.
falciparum gDNA were found in the placenta; no plasmodial gDNA was detected in peripheral blood after delivery. Abbreviations are as follows:
MW, molecular weight; bp, base pair; B, patient peripheral blood sample; niB, non-infected human peripheral blood; P, patient placenta sample;
niP, non-infected human placenta; C-, negative control, absence of nuclear material; Pv+ and Pf+, positive controls representing amplification
product of P. vivax (120 bp) and P. falciparum (200 bp) ssrRNA gene.
Carvalho et al. Malaria Journal 2011, 10:178
http://www.malariajournal.com/content/10/1/178
Page 4 of 5Moreover, it demonstrates the necessity during preg-
nancy to consider asymptomatic plasmodial infections
as a potential complication, and urges careful patient
f o l l o w - u pe v e nw h e np e r i p heral parasitaemia seems
absent following drug treatment. Highly sensitive techni-
ques are available and must be used as diagnostic tools,
especially in high-risk groups such as pregnant women.
Additional material
Additional file 1: Presence confirmation of P. falciparum- and P.
vivax-infected erythrocytes in the placental tissue collected after
foetal loss. Agarose gel electrophoresis of semi-nested multiplex PCR
(SnM-PCR) amplified products in the presence of species-specific human
malaria parasite oligonucleotides specific for P. ovale, P. malariae, P. vivax
or P. falciparum ssrRNA gene. Both P. vivax and P. falciparum gDNA were
found in the placenta. Abbreviations are as follows: MW, molecular
weight; bp, base pair; S, patient placental sample; C-, negative control,
absence of nuclear material; Po+, Pm+, Pv+ and Pf+, positive controls
representing amplification product of P. ovale (436 bp), P. malariae (269
bp), P. vivax (499 bp) and P. falciparum (395 bp) ssrRNA gene.
Additional file 2: Molecular diagnosis of Plasmodium falciparum
infection performed two months after delivery. Agarose gel
electrophoresis representing nested-PCR performed in the presence of
patient’s peripheral blood collected two months after delivery and
species-specific human malaria parasite oligonucleotides (VIV or FAL,
specific for P. vivax or P. falciparum ssrRNA gene, respectively). Only P.
falciparum gDNA was detected in peripheral blood. Abbreviations are as
follows: MW, molecular weight; bp, base pair; B, patient peripheral blood
sample; niB, non-infected peripheral blood sample; C-, negative control,
absence of nuclear material; Pv+ and Pf+, positive controls representing
amplification product of P. vivax (120 bp) and P. falciparum (200 bp)
ssrRNA gene.
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